<?xml version="1.0" encoding="UTF-8"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-10-19T01:52:46Z</responseDate><request verb="GetRecord" identifier="oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/12373" metadataPrefix="oai_dc">https://ebyu-rdlopen.rawdatalibrary.net/oai/request</request><GetRecord><record><header><identifier>oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/12373</identifier><datestamp>2026-10-18T21:13:23Z</datestamp><setSpec>openaire</setSpec><setSpec>driver</setSpec><setSpec>com_ebyu_10000</setSpec><setSpec>col_ebyu_10001</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:title>Tailoring adjuvant chemotherapy by circulating tumor DNA (ctDNA) in older patients with stage II-III colon cancer</dc:title><dc:creator>Akagündüz, Baran</dc:creator><dc:creator>Guven, Deniz Can</dc:creator><dc:creator>Ozer, Muhammet</dc:creator><dc:creator>Okten, Ilker Nihat</dc:creator><dc:creator>Atag, Elif</dc:creator><dc:creator>Unek, İlkay Tugba</dc:creator><dc:creator>Tatli, Ali Murat</dc:creator><dc:creator>Karaoglu, Aziz</dc:creator><dc:subject>Adjuvant chemotherapy</dc:subject><dc:subject>Colon cancer</dc:subject><dc:subject>ctDNA</dc:subject><dc:subject>Older patients</dc:subject><dc:subject>Aged</dc:subject><dc:subject>Biomarkers, Tumor</dc:subject><dc:subject>Chemotherapy, Adjuvant</dc:subject><dc:subject>Circulating Tumor DNA</dc:subject><dc:subject>Colonic Neoplasms</dc:subject><dc:subject>Humans</dc:subject><dc:subject>Neoplasm Recurrence, Local</dc:subject><dc:subject>Neoplasm Staging</dc:subject><dc:subject>fluorouracil</dc:subject><dc:subject>oxaliplatin</dc:subject><dc:subject>pembrolizumab</dc:subject><dc:subject>tumor marker</dc:subject><dc:subject>Article</dc:subject><dc:subject>cancer chemotherapy</dc:subject><dc:subject>cancer recurrence</dc:subject><dc:subject>cancer staging</dc:subject><dc:subject>cognition</dc:subject><dc:subject>comorbidity</dc:subject><dc:subject>decision making</dc:subject><dc:subject>disease free survival</dc:subject><dc:subject>ECOG Performance Status</dc:subject><dc:subject>follow up</dc:subject><dc:subject>geriatric patient</dc:subject><dc:subject>human</dc:subject><dc:subject>Karnofsky Performance Status</dc:subject><dc:subject>microsatellite instability</dc:subject><dc:publisher>Elsevier Ltd</dc:publisher><dc:date>2023</dc:date><dc:type>Article</dc:type><dc:identifier>https://rdlopen.rawdatalibrary.net/r/ebyu/12373</dc:identifier><dc:identifier>https://doi.org/10.1016/j.jgo.2022.08.016</dc:identifier><dc:identifier>1879-4068</dc:identifier><dc:language>en</dc:language><dc:relation>Journal of Geriatric Oncology</dc:relation><dc:rights>info:eu-repo/semantics/openAccess</dc:rights><dc:type>info:eu-repo/semantics/article</dc:type><dc:identifier>https://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/12373</dc:identifier></oai_dc:dc></metadata></record></GetRecord></OAI-PMH>